CRSP icon

CRISPR Therapeutics

42.52 USD
+2.90
7.32%
Updated Feb 12, 12:42 PM EST
1 day
7.32%
5 days
-0.44%
1 month
9.45%
3 months
-16.18%
6 months
-9.36%
Year to date
2.63%
1 year
-44.37%
5 years
-26.37%
10 years
201.77%
 

About: Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.

Employees: 407

0
Funds holding %
of 6,831 funds
0
Analysts bullish %
of 7 analysts

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

0% more funds holding in top 10

Funds holding in top 10: 5 [Q2] → 5 (+0) [Q3]

0.97% less ownership

Funds ownership: 71.19% [Q2] → 70.22% (-0.97%) [Q3]

2% less repeat investments, than reductions

Existing positions increased: 127 | Existing positions reduced: 129

8% less funds holding

Funds holding: 442 [Q2] → 407 (-35) [Q3]

14% less capital invested

Capital invested by funds: $3.26B [Q2] → $2.81B (-$455M) [Q3]

34% less call options, than puts

Call options by funds: $68.2M | Put options by funds: $103M

38% less first-time investments, than exits

New positions opened: 45 | Existing positions closed: 73

Research analyst outlook

7 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$48
13%
upside
Avg. target
$74
74%
upside
High target
$94
121%
upside

7 analyst ratings

positive
71%
neutral
29%
negative
0%
RBC Capital
Luca Issi
37% 1-year accuracy
22 / 59 met price target
13%upside
$48
Sector Perform
Maintained
12 Feb 2025
Needham
Gil Blum
17% 1-year accuracy
29 / 172 met price target
98%upside
$84
Buy
Reiterated
12 Feb 2025
Barclays
Gena Wang
21% 1-year accuracy
6 / 29 met price target
32%upside
$56
Equal-Weight
Maintained
12 Feb 2025
HC Wainwright & Co.
Mitchell Kapoor
30% 1-year accuracy
51 / 172 met price target
53%upside
$65
Buy
Initiated
3 Feb 2025
B of A Securities
Geoff Meacham
41% 1-year accuracy
11 / 27 met price target
100%upside
$85
Buy
Maintained
7 Jan 2025

Financial journalist opinion

Based on 21 articles about CRSP published over the past 30 days

Positive
Zacks Investment Research
2 hours ago
CRISPR Therapeutics Q4 Earnings and Revenues Surpass Estimates
CRSP reports encouraging fourth-quarter results. The commercial launch of the first CRISPR-based gene therapy, Casgevy, is progressing well.
CRISPR Therapeutics Q4 Earnings and Revenues Surpass Estimates
Negative
Zacks Investment Research
18 hours ago
CRISPR Therapeutics AG (CRSP) Reports Q4 Loss, Tops Revenue Estimates
CRISPR Therapeutics AG (CRSP) came out with a quarterly loss of $0.44 per share versus the Zacks Consensus Estimate of a loss of $1.15. This compares to earnings of $1.10 per share a year ago.
CRISPR Therapeutics AG (CRSP) Reports Q4 Loss, Tops Revenue Estimates
Neutral
GlobeNewsWire
20 hours ago
CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results
-2025 is poised to be a catalyst-rich year with key updates across several programs- -Ongoing launch of CASGEVY ® continues to gain momentum; new cell patient collection initiations expected to significantly grow in 2025- -More than 50 authorized treatment centers (ATCs) activated globally for CASGEVY, and more than 50 patients have had cells collected across all regions as of the end of 2024- -Clinical trials ongoing for next-generation CAR T product candidates, CTX112™ and CTX131™, targeting CD19 and CD70 across multiple indications; updates for CTX112 in oncology and autoimmune diseases are expected in mid-2025 with CTX131 updates expected in 2025- -CRISPR Therapeutics and Nkure Therapeutics Private Limited establish global strategic partnership to co-develop and co-commercialize CTX112 in India- -Clinical trials ongoing for in vivo gene editing product candidates, CTX310™ and CTX320™ targeting ANGPTL3 and LPA, respectively; updates expected in the first half of 2025- -Strong balance sheet with approximately $1.9 billion in cash, cash equivalents, and marketable securities as of December 31, 2024- ZUG, Switzerland and BOSTON, Feb. 11, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today reported financial results for the fourth quarter and full year ended December 31, 2024. "With continued advancements across our commercial and clinical portfolio, CRISPR Therapeutics is poised to make meaningful strides in transforming the landscape of medicine.
CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results
Positive
The Motley Fool
2 days ago
Investing $1,000 in These 3 Beaten-Down Stocks Could Be a Brilliant Move
Investing in stocks that aren't performing well can be a good move, but only if there are good reasons to think they will recover. That isn't the case for many companies that have lagged broader equities.
Investing $1,000 in These 3 Beaten-Down Stocks Could Be a Brilliant Move
Neutral
Zacks Investment Research
5 days ago
CRISPR Therapeutics Stock Before Q4 Earnings: To Buy or Not to Buy?
On CRSP's fourth-quarter 2024 earnings call, investors' focus will likely be on the sales figure of Casgevy, its first marketed product.
CRISPR Therapeutics Stock Before Q4 Earnings: To Buy or Not to Buy?
Neutral
Seeking Alpha
6 days ago
CRISPR Therapeutics AG (CRSP) Guggenheim SMID Cap Biotech Conference (Transcript)
CRISPR Therapeutics AG (NASDAQ:CRSP ) Guggenheim SMID Cap Biotech Conference Transcript February 6, 2025 2:00 PM ET Company Participants Samarth Kulkarni - Chief Executive Officer Conference Call Participants Debjit Chattopadhyay - Guggenheim Partners Debjit Chattopadhyay And thank you for joining Guggenheim during our second SMID Cap conference. I am Debjit, one of the therapeutic analysts here, and joining me from CRISPR Therapeutics is CEO, Samarth Kulkarni.
CRISPR Therapeutics AG (CRSP) Guggenheim SMID Cap Biotech Conference (Transcript)
Positive
Seeking Alpha
6 days ago
Crispr Therapeutics: Why I've Become Even More Bullish (Rating Upgrade)
Crispr Therapeutics AG's partnership with Vertex Pharmaceuticals offers financial support, mentorship, and validation, enhancing Crispr's approach and technology. Despite slower-than-expected Casgevy enrollment, Crispr's strong cash position and diversified drug pipeline bolster its long-term growth potential. Clinical progress includes expanding authorized treatment centers for Casgevy and advancing multiple drug candidates in hemoglobinopathies, CAR-T, and in vivo programs.
Crispr Therapeutics: Why I've Become Even More Bullish (Rating Upgrade)
Positive
Zacks Investment Research
1 week ago
Why CRISPR Therapeutics AG (CRSP) Outpaced the Stock Market Today
In the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $40.49, marking a +1.23% move from the previous day.
Why CRISPR Therapeutics AG (CRSP) Outpaced the Stock Market Today
Positive
Zacks Investment Research
1 week ago
Are These 5 Biotech Stocks Set to Beat Q4 Earnings Estimates?
Let us look at some biotech stocks, AMGN, CRSP, MRNA, SRPT and VRTX, which are poised to beat on fourth-quarter earnings.
Are These 5 Biotech Stocks Set to Beat Q4 Earnings Estimates?
Neutral
Zacks Investment Research
1 week ago
CRISPR Therapeutics AG (CRSP) Declines More Than Market: Some Information for Investors
In the closing of the recent trading day, CRISPR Therapeutics AG (CRSP) stood at $41.21, denoting a -1.44% change from the preceding trading day.
CRISPR Therapeutics AG (CRSP) Declines More Than Market: Some Information for Investors
Charts implemented using Lightweight Charts™